Serum immunoglobulin free light-chain measurement in primary amyloidosis: Prognostic value and correlations with clinical features

Shaji K Kumar, Angela Dispenzieri, Jerry A. Katzmann, Dirk R. Larson, Colin L. Colby, Martha Lacy, Suzanne R. Hayman, Francis K. Buadi, Nelson Leung, Steve R. Zeldenrust, Marina Ramirez-Alvarado, Raynell J. Clark, Robert A. Kyle, S Vincent Rajkumar, Morie Gertz

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 patients with newly diagnosed AL. The plasma cell clone was λ in 72% patients, and κ in 28% patients. κ-AL had more GI tract and liver involvement, where as renal involvement was more with λ-AL. While the overall survival (OS) was similar for κ and λ-AL, the median OS for those without an identifiable serum heavy chain was significantly shorter (12.6 vs 29.9 months; P = .02). The OS was shorter among those with a higher dFLC (involved FLC-uninvolved FLC; κ > 29.4 mg/dL or λ > 18.2 mg/dL using median for cutoff); 10.9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL.

Original languageEnglish (US)
Pages (from-to)5126-5129
Number of pages4
JournalBlood
Volume116
Issue number24
DOIs
StatePublished - Dec 9 2010

Fingerprint

Immunoglobulin Light Chains
Amyloidosis
Immunoglobulins
Light
Serum
Survival
Clone cells
Plasma Cells
Amyloid
Gastrointestinal Tract
Liver
Multivariate Analysis
Clone Cells
Primary amyloidosis
Kidney
Plasmas

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Serum immunoglobulin free light-chain measurement in primary amyloidosis : Prognostic value and correlations with clinical features. / Kumar, Shaji K; Dispenzieri, Angela; Katzmann, Jerry A.; Larson, Dirk R.; Colby, Colin L.; Lacy, Martha; Hayman, Suzanne R.; Buadi, Francis K.; Leung, Nelson; Zeldenrust, Steve R.; Ramirez-Alvarado, Marina; Clark, Raynell J.; Kyle, Robert A.; Rajkumar, S Vincent; Gertz, Morie.

In: Blood, Vol. 116, No. 24, 09.12.2010, p. 5126-5129.

Research output: Contribution to journalArticle

Kumar, Shaji K ; Dispenzieri, Angela ; Katzmann, Jerry A. ; Larson, Dirk R. ; Colby, Colin L. ; Lacy, Martha ; Hayman, Suzanne R. ; Buadi, Francis K. ; Leung, Nelson ; Zeldenrust, Steve R. ; Ramirez-Alvarado, Marina ; Clark, Raynell J. ; Kyle, Robert A. ; Rajkumar, S Vincent ; Gertz, Morie. / Serum immunoglobulin free light-chain measurement in primary amyloidosis : Prognostic value and correlations with clinical features. In: Blood. 2010 ; Vol. 116, No. 24. pp. 5126-5129.
@article{584ea8dde40b49d69686d4d423bd391f,
title = "Serum immunoglobulin free light-chain measurement in primary amyloidosis: Prognostic value and correlations with clinical features",
abstract = "Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 patients with newly diagnosed AL. The plasma cell clone was λ in 72{\%} patients, and κ in 28{\%} patients. κ-AL had more GI tract and liver involvement, where as renal involvement was more with λ-AL. While the overall survival (OS) was similar for κ and λ-AL, the median OS for those without an identifiable serum heavy chain was significantly shorter (12.6 vs 29.9 months; P = .02). The OS was shorter among those with a higher dFLC (involved FLC-uninvolved FLC; κ > 29.4 mg/dL or λ > 18.2 mg/dL using median for cutoff); 10.9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL.",
author = "Kumar, {Shaji K} and Angela Dispenzieri and Katzmann, {Jerry A.} and Larson, {Dirk R.} and Colby, {Colin L.} and Martha Lacy and Hayman, {Suzanne R.} and Buadi, {Francis K.} and Nelson Leung and Zeldenrust, {Steve R.} and Marina Ramirez-Alvarado and Clark, {Raynell J.} and Kyle, {Robert A.} and Rajkumar, {S Vincent} and Morie Gertz",
year = "2010",
month = "12",
day = "9",
doi = "10.1182/blood-2010-06-290668",
language = "English (US)",
volume = "116",
pages = "5126--5129",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Serum immunoglobulin free light-chain measurement in primary amyloidosis

T2 - Prognostic value and correlations with clinical features

AU - Kumar, Shaji K

AU - Dispenzieri, Angela

AU - Katzmann, Jerry A.

AU - Larson, Dirk R.

AU - Colby, Colin L.

AU - Lacy, Martha

AU - Hayman, Suzanne R.

AU - Buadi, Francis K.

AU - Leung, Nelson

AU - Zeldenrust, Steve R.

AU - Ramirez-Alvarado, Marina

AU - Clark, Raynell J.

AU - Kyle, Robert A.

AU - Rajkumar, S Vincent

AU - Gertz, Morie

PY - 2010/12/9

Y1 - 2010/12/9

N2 - Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 patients with newly diagnosed AL. The plasma cell clone was λ in 72% patients, and κ in 28% patients. κ-AL had more GI tract and liver involvement, where as renal involvement was more with λ-AL. While the overall survival (OS) was similar for κ and λ-AL, the median OS for those without an identifiable serum heavy chain was significantly shorter (12.6 vs 29.9 months; P = .02). The OS was shorter among those with a higher dFLC (involved FLC-uninvolved FLC; κ > 29.4 mg/dL or λ > 18.2 mg/dL using median for cutoff); 10.9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL.

AB - Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 patients with newly diagnosed AL. The plasma cell clone was λ in 72% patients, and κ in 28% patients. κ-AL had more GI tract and liver involvement, where as renal involvement was more with λ-AL. While the overall survival (OS) was similar for κ and λ-AL, the median OS for those without an identifiable serum heavy chain was significantly shorter (12.6 vs 29.9 months; P = .02). The OS was shorter among those with a higher dFLC (involved FLC-uninvolved FLC; κ > 29.4 mg/dL or λ > 18.2 mg/dL using median for cutoff); 10.9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL.

UR - http://www.scopus.com/inward/record.url?scp=78650037877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650037877&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-06-290668

DO - 10.1182/blood-2010-06-290668

M3 - Article

C2 - 20798235

AN - SCOPUS:78650037877

VL - 116

SP - 5126

EP - 5129

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -